Publications

BibTex format

@article{Achison:2022:10.1002/jcsm.12934,
author = {Achison, M and Adamson, S and Akpan, A and Aspray, T and Avenell, A and Band, M and Bashir, T and Burton, L and Cvoro, V and Donnan, P and Duncan, G and George, J and Gordon, A and Gregson, C and Hapca, A and Henderson, E and Hume, C and Jackson, T and Kemp, P and Kerr, S and Kilgour, A and Lyell, V and Masud, T and McKenzie, A and McKenzie, E and Patel, H and Pilvynte, K and Roberts, H and Rossios, C and Sayer, A and Smith, K and Soiza, R and Steves, C and Struthers, A and Sumukadas, D and Tiwari, D and Whitney, J and Witham, M},
doi = {10.1002/jcsm.12934},
journal = {Journal of Cachexia, Sarcopenia and Muscle},
pages = {858--871},
title = {Effect of Perindopril or Leucine on physical performance in older people with sarcopenia: the LACE randomised controlled trial},
url = {http://dx.doi.org/10.1002/jcsm.12934},
volume = {13},
year = {2022}
}

Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - Background:This trial aimed to determine the efficacy of leucine and/or perindopril in improving physical function in older people with sarcopenia.Methods:Placebo-controlled, parallel group, double-blind, randomised two-by-two factorial trial. We recruited adults aged ≥70 years with sarcopenia, defined as low gait speed (<0.8 m/s on 4m walk) and/or low handgrip strength (women <20kg, men <30kg) plus low muscle mass (using sex and BMI category-specific thresholds derived from normative UK BioBank data) from 14 UK centres. Eligible participants were randomised to perindopril 4mg or placebo, and to oral leucine powder 2.5g or placebo thrice daily. The primary outcome was the between-group difference in the Short Physical Performance Battery (SPPB) score over 12-month follow-up by repeated-measures mixed models. Results were combined with existing systematic reviews using random-effects meta-analysis to derive summary estimates of treatment efficacy.Results:We screened 320 people and randomised 145 participants compared to an original target of 440 participants. For perindopril (n=73, mean age 79 [SD 6], female sex 39 [53%], mean SPPB 7.1 [SD 2.3]) vs no perindopril (n=72, mean age 79 [SD 6], female sex 39 [54%], mean SPPB 6.9 [SD 2.4]), medianadherence to perindopril was lower (76% vs 96%; p<0.001). Perindopril did not improve the primary outcome (adjusted treatment effect -0.1 points [95%CI -1.2 to 1.0], p=0.89). No significant treatmentbenefit was seen for any secondary outcome including muscle mass (adjusted treatment effect -0.4kg [95%CI -1.1 to 0.3], p=0.27). More adverse events occurred in the perindopril group (218 vs 165) butfalls rates were similar. For leucine (n=72, mean age 78 [SD 6], female sex 38 [53%], mean SPPB 7.0 [SD 2.1]) vs no leucine (n=72, mean age 79 [SD 6], female sex 40 [55%], mean SPPB 7.0 [SD 2.5]), 5 median adherence was the same in both groups (76% vs 76%; p=0.99). Leucine did not improve the primary outcome (adjusted treatme
AU  - Achison,M
AU  - Adamson,S
AU  - Akpan,A
AU  - Aspray,T
AU  - Avenell,A
AU  - Band,M
AU  - Bashir,T
AU  - Burton,L
AU  - Cvoro,V
AU  - Donnan,P
AU  - Duncan,G
AU  - George,J
AU  - Gordon,A
AU  - Gregson,C
AU  - Hapca,A
AU  - Henderson,E
AU  - Hume,C
AU  - Jackson,T
AU  - Kemp,P
AU  - Kerr,S
AU  - Kilgour,A
AU  - Lyell,V
AU  - Masud,T
AU  - McKenzie,A
AU  - McKenzie,E
AU  - Patel,H
AU  - Pilvynte,K
AU  - Roberts,H
AU  - Rossios,C
AU  - Sayer,A
AU  - Smith,K
AU  - Soiza,R
AU  - Steves,C
AU  - Struthers,A
AU  - Sumukadas,D
AU  - Tiwari,D
AU  - Whitney,J
AU  - Witham,M
DO  - 10.1002/jcsm.12934
EP  - 871
PY  - 2022///
SN  - 2190-6009
SP  - 858
TI  - Effect of Perindopril or Leucine on physical performance in older people with sarcopenia: the LACE randomised controlled trial
T2  - Journal of Cachexia, Sarcopenia and Muscle
UR  - http://dx.doi.org/10.1002/jcsm.12934
UR  - https://onlinelibrary.wiley.com/doi/10.1002/jcsm.12934
UR  - http://hdl.handle.net/10044/1/94558
VL  - 13
ER  -

Download

DrPaulKemp

Contact

Location

Summary

Citation

BibTex format

RIS format (EndNote, RefMan)